

- Runyon BA. Current concepts: Care of patients with ascites. *N Engl J Med* 1994;330:337–342.
- Garrison RN, Kaelin LD, Galloway RH, et al. Malignant ascites. Clinical and experimental observations. *Ann Surg* 1986;203:644–651.
- Runyon BA. Malignancy-related ascites and ascitic fluid “humoral tests of malignancy.” *J Clin Gastroenterol* 1994;18:94–98.
- Smith EM, Jayson GC. The current and future management of malignant ascites. *Clin Oncol* 2003;15:59–72.
- Saif MW, Siddiqui IAP, Sohail MA. Management of ascites due to gastrointestinal malignancy. *Ann Saudi Med* 2009;29:369–377.
- Gotloib L, Shostak A. The functional anatomy of the peritoneum as a dialyzing membrane. *Peritoneal Dialysis* 1990;1:27.
- Nolph KD, Miller F, Rubin J, et al. New directions in peritoneal dialysis concepts and applications. *Kidney Int Suppl* 1980;10:S111–S116.
- Cavazzoni E, Bugiantella W, Graziosi L, et al. Malignant ascites: pathophysiology and treatment. *Int J Clin Oncol* 2013;18:1–9.
- Lifshitz S. Ascites, pathophysiology and control measures. *Int J Radiat Oncol Biol Phys* 1982;8:1423–1426.
- Feldman GB, Knapp RC. Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. *Am J Obstet Gynecol* 1974;119:991–994.
- Rose BD, Post TW. Edematous states. In Rose BD, Post TW, eds. *Clinical Physiology of Acid-base and Electrolyte Disorders*. New York: McGraw-Hill Professional; 2001:478–534.
- Starling EH. On the absorption of fluids from the connective tissue spaces. *J Physiol* 1896;19:312–326.
- Fastaia J, Dumont AE. Pathogenesis of ascites in mice with peritoneal carcinomatosis. *J Natl Cancer Inst* 1976;56:547–550.
- Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* 1996;86:353–364.
- Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. *Cancer Res* 1995;55:360–368.
- Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. *Am J Pathol* 1998;153:1249–1256.
- Beecham JB, Kucera P, Helmkamp BF, et al. Peritoneal angiogenesis in patients with ascites. *Gynecol Oncol* 1983;15:142–145.
- Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. *Cancer* 1999;85:178–187.
- Santin AD, Hermonat PL, Ravaggi A, et al. Secretion of vascular endothelial growth factor in ovarian cancer. *Eur J Gynaecol Oncol* 1999;20:177–181.
- Zebrowski BK, Liu W, Ramirez K, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. *Ann Surg Oncol* 1999;6:373–378.
- Beattie CJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. *Clin Cancer Res* 1998;4:1899–1902.
- Brown PD. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. *Adv Enzyme Regul* 1995;35:293–301.
- Brown PD. Matrix metalloproteinase inhibitors. *Breast Cancer Res Treat* 1998;52:125–136.
- Parsons SL, Watson SA, Steele RJ. Malignant ascites. *Br J Surg* 1996;83:6–14.
- Watson SA, Morris TM, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. *Cancer Res* 1995;55:3629–3633.
- Nagy JA, Morgan ES, Herzberg KT, et al. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. *Cancer Res* 1995;55:376–385.
- Hirabayashi K, Graham J. Genesis of ascites in ovarian cancer. *Am J Obstet Gynecol* 1970;106:492–497.
- Tamsma J. The pathogenesis of malignant ascites. *Cancer Treat Res* 2007;134:109–118.
- Enck RE. Malignant ascites. *Am J Hosp Palliat Care* 2002;19:7–8.
- Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. *Hepatology* 1988;8:1104–1109.
- Chung M, Kozuch P. Treatment of malignant ascites. *Curr Treat Options Oncol* 2008;9:215–233.
- Holm-Nielsen P. Pathogenesis of ascites in peritoneal carcinomatosis. *Acta Pathol Microbiol Scand* 1953;33:10–21.
- Mactier RA. Kinetics of ultrafiltration with glucose and alternative osmotic agents. In Twardowski ZJ, Nolph KD, Khanna R, eds. *Peritoneal dialysis, new concepts and applications*. New York: Churchill Livingstone; 1990:29–52.
- Bronskill MJ, Bush RS, Ege GN. A quantitative measurement of peritoneal drainage in malignant ascites. *Cancer* 1977;40:2375–2380.
- Coates G, Bush RS, Aspin N. A study of ascites using lymphoscintigraphy with 99m Tc-sulfur colloid. *Radiology* 1973;107:577–583.
- Feldman GB, Knapp RC, Order SE, et al. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. *Cancer Res* 1972;32:1663–1666.
- Goldberg BB, Goodman GA, Clearfield HR. Evaluation of ascites by ultrasound. *Radiology* 1970;96:15–22.
- Risson JR, Macovei I, Look M, et al. Cirrhotic and malignant ascites: differential CT diagnosis. *Diagn Interv Imaging* 2012;93:365–370.
- Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. *Ann Oncol* 2007;18:945–949.
- Parsons SL, Lang MW, Steele RJ. Malignant ascites: A 2-year review from a teaching hospital. *Eur J Surg Oncol* 1996;22:237–239.
- Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. *Ann Intern Med* 1992;117:215–220.
- Runyon BA. Amylase levels in ascitic fluid. *J Clin Gastroenterol* 1987;9:172–174.
- Siddiqui RA, Kochhar R, Singh V, et al. Evaluation of fibronectin as a marker of malignant ascites. *J Gastroenterol Hepatol* 1992;7:161–164.
- Colli A, Buccino G, Cociolo M, et al. Diagnostic accuracy of sialic acid in the diagnosis of malignant ascites. *Cancer* 1989;63:912–916.
- Pazdur R, Coia LR, Hoskins WJ, et al. *Cancer management: a multidisciplinary approach*. Seattle, WA: P.R.R. Inc.; 2003.
- Tangkijvanich P, Tresukosol D, Sampatanukul P, et al. Telomerase assay for differentiating between malignancy-related and nonmalignant ascites. *Clin Cancer Res* 1999;5:2470–2475.
- Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. *J Pain Symptom Manage* 1998;16:96–101.
- Sharma S, Walsh D. Management of symptomatic malignant ascites with diuretics: two case reports and a review of the literature. *J Pain Symptom Manage* 1995;10:237–242.
- Pockros PJ, Esrason KT, Nguyen C, et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. *Gastroenterology* 1992;103:1302–1306.
- Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. *Eur J Cancer* 2006;42:589–597.
- Greenway B, Johnson PJ, Williams R. Control of malignant ascites with spironolactone. *Br J Surg* 1982;69:441–442.
- Keen A, Fitzgerald D, Bryant A, et al. Management of drainage for malignant ascites in gynaecological cancer. *Cochrane Database Syst Rev* 2010;1:CD007794.
- Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. *Gastroenterology* 1987;93:234–241.
- Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. *Gastroenterology* 1988;94:1493–1502.
- McNamara P. Paracentesis – an effective method of symptom control in the palliative care setting? *Palliat Med* 2000;14:62–64.
- Salerno F, Badalamenti S, Incerti P, et al. Repeated paracentesis and i.v. albumin infusion to treat “tense” ascites in cirrhotic patients. A safe alternative therapy. *J Hepatol* 1987;5:102–108.
- Fischer DS. Abdominal paracentesis for malignant ascites. *Arch Int Med* 1979;139:235.
- Gines P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites. *N Engl J Med* 2004;350:1646–1654.
- Covey AM. Management of malignant pleural effusions and ascites. *J Support Oncol* 2005;3:169–176.
- Appelqvist P, Silvo J, Salmela L, et al. On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed? *J Surg Oncol* 1982;20:238–242.
- Gotlieb WH, Feldman B, Feldman-Moran O, et al. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. *Gynecol Oncol* 1998;71:381–385.
- Belfort MA, Stevens PJ, DeHaek K, et al. A new approach to the management of malignant ascites; a permanently implanted abdominal drain. *Eur J Surg Oncol* 1990;16:47–53.
- Richard HM 3rd, Coldwell DM, Boyd-Kranis RL, et al. Pleurx tunneled catheter in the management of malignant ascites. *J Vasc Interv Radiol* 2001;12:373–375.
- Rosenberg S, Courtney A, Nemcek AA Jr, et al. Comparison of percutaneous management techniques for recurrent malignant ascites. *J Vasc Interv Radiol* 2004;15:1129–1131.
- Fleming ND, Alvarez-Secord A, Von Gruenigen V, et al. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. *J Pain Symptom Manage* 2009;38:341–349.
- Adam RA, Adam YG. Malignant ascites: past, present, and future. *J Am Coll Surg* 2004;198:999–1011.
- Barnett TD, Rubins J. Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites: a simplified percutaneous approach. *J Vasc Interv Radiol* 2002;13:379–383.
- Lee A, Lau TN, Yeong KY. Indwelling catheters for the management of malignant ascites. *Support Care Cancer* 2000;8:493–499.
- Stokes LS. Percutaneous management of malignant fluid collections. *Sem Intervent Radiol* 2007;24:398–408.
- Seike M, Maetani I, Sakai Y. Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis. *J Gastroenterol Hepatol* 2007;22:2161–2166.

71. Mulvany D. Vesico-coelomic drainage for the relief of ascites. *Lancet* 1955; 266:748–749.
72. Tarin D, Price JE, Kettlewell MG, et al. Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts. *Br Med J* 1984;288:749–751.
73. Cheung DK, Raaf JH. Selection of patients with malignant ascites for a peritoneovenous shunt. *Cancer* 1982;50:1204–1209.
74. Helzberg JH, Greenberger NJ. Peritoneovenous shunts in malignant ascites. *Dig Dis Sci* 1985;30:1104–1107.
75. Qazi R, Savlov ED. Peritoneovenous shunt for palliation of malignant ascites. *Cancer* 1982;49:600–602.
76. Link KH, Roitman M, Holtappels M, et al. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. *Surg Oncol Clin North Am* 2003; 12:865–872.
77. Maiche AG. Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin. *Anticancer Drugs* 1994;5:305–308.
78. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. *J Cancer Res Clin Oncol* 1992;118:547–550.
79. Ostrowski MJ. An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin. *Cancer* 1986;57:721–727.
80. Schilsky RL, Choi KE, Grayhack J, et al. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. *J Clin Oncol* 1990;8:2054–2061.
81. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. *JAMA* 1955;159:1704–1707.
82. Lund RH, Newkirk JB. Peritoneovenous shunting system for surgical management of ascites. *Contemp Surg* 1979;14:31–45.
83. Stuart GC, Nation JG, Snider DD, et al. Intraperitoneal interferon in the management of malignant ascites. *Cancer* 1993;71:2027–2030.
84. Sugarbaker PH. Peritonectomy procedures. In Sugarbaker PH, ed. *Peritoneal Carcinomatosis: Principles of Management*. New York: Springer; 1996:235–253.
85. Sugarbaker PH, Chang D, Koslowe P. Peritoneal carcinomatosis from appendiceal cancer: A paradigm for treatment of abdomino-pelvic dissemination of gastrointestinal malignancy. *Acta Chirurgica Austriaca* 1996;28:4–8.
86. Los G, Smals OA, Van Vugt MJ, et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. *Cancer Res* 1992;52:1252–1258.
87. Gilly FN, Carry PY, Brachet A, et al. Treatment of malignant peritoneal effusion in digestive and ovarian cancer. *Med Oncol Tumor Pharmacother* 1992;9:177–181.
88. Loggie BW, Fleming RA, McQuellon RP, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. *Am Surg* 2000;66:561–568.
89. Loggie BW. Prospective trial for the treatment of malignant peritoneal mesothelioma. *Am Surg* 2001;67:999–1003.
90. Loggie BW, Perini M, Fleming RA, et al. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. *Am Surg* 1997;63:137–143.
91. Randle RW, Sweet KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. *Ann Surg Oncol* 2014;21:1474–1479.
92. Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. *Eur J Surg Oncol* 2010;36:456–462.
93. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. *J Clin Oncol* 2009;27:6237–6242.
94. Facchiano E, Scaringi S, Kianmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. *Eur J Surg Oncol* 2008;34:154–158.
95. Valle M, Van Der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients. *J Surg Oncol* 2009;100:331–334.
96. Facchiano E, Risto D, Kianmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature. *Ann Surg Oncol* 2012;19:2946–2950.
97. Hirte HW, Miller D, Tonkin K, et al. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. *Gynecol Oncol* 1997;64:80–87.
98. Rath U, Kaufmann M, Schmid H, et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. *Eur J Cancer* 1991;27:121–125.
99. Sherer DM, Eliakim R, Abulafia O. The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. *Gynecol Obstet Invest* 2000;50:217–224.
100. Stoelcker B, Echtenacher B, Weich HA, et al. VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. *J Interferon Cytokine Res* 2000;20:511–517.
101. Gebbia V, Russo A, Gebbia N, et al. Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy. *In Vivo* 1991;5:579–582.
102. Gebbia N, Mannino R, Di Dino A, et al. Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients. *Anticancer Res* 1994;14:739–745.
103. Katano M, Morisaki T. The past, the present and future of the OK-432 therapy for patients with malignant effusions. *Anticancer Res* 1998;18:3917–3925.
104. Torisu M, Katano M, Kimura Y, et al. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. *Surgery* 1983;93:357–364.
105. Yamaguchi Y, Satoh Y, Miyahara E, et al. Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. *Anticancer Res* 1995;15:2201–2206.
106. Currie JL, Gall S, Weed JC Jr, et al. Intracavitary *Corynebacterium parvum* for treatment of malignant effusions. *Gynecol Oncol* 1983;16:6–14.
107. Buckman R, De Angelis C, Shaw P, et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. *Gynecol Oncol* 1992;47:102–109.
108. Xu L, Yoneda J, Herrera C, et al. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. *Int J Oncol* 2000;16:445–454.
109. Verheul HM, Hoekman K, Jorna AS, et al. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. *Oncologist* 2000;5:45–50.
110. El-Shami K, Elsaid A, El-Kerm Y. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. *J Clin Oncol* 2007;25:9043.
111. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. *Blood* 2001;98:2526–2534.
112. De Angelis M, Buley ID, Heryet A, et al. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4. *Cytopathology* 1992;3:111–117.
113. Diaz-Arias AA, Loy TS, Bickel JT, et al. Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases. *Diagn Cytopathol* 1993;9:516–521.
114. Passebosch-Faure K, Li G, Lambert C, et al. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. *Clin Cancer Res* 2005;11:6862–6867.
115. Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD5 antibody: a phase I/II study. *Clin Cancer Res* 2007;13:3899–3905.
116. Heiss MM, Strohle MA, Jager M, et al. Immunotherapy of malignant ascites with trifunctional antibodies. *Int J Cancer* 2005;117:435–443.
117. Krueger CM. Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: A phase II study. *J Clin Oncol* 2008;26:15529.
118. Parsons SL, Kutarska E, Koralewski P. Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: results of a phase II/III study. *J Clin Oncol* 2007;25:5520.
119. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. *Int J Cancer* 2010; 127:2209–2221.
120. Mackey JR, Wood L, Nabholz JM, et al. A Phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites. *J Pain Symp Manage* 2000;19:193–199.
121. Dybicki J, Balchum OJ, Meneely GR. Treatment of pleural and peritoneal effusion with intracavitary colloidal radiogold (Au-198). *Arch Int Med* 1958;104:802–814.
122. Rosenshein NB, Leichner PK, Vogelsang G. Radiocolloids in the treatment of ovarian cancer. *Obstet Gynecol Surv* 1979;34:708–720.
123. Ariel IM, Oropeza R, Pack G.T. Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients. *Cancer* 1966;19:1096–1102.
124. Card RY, Cole DR, Henschke UK. Summary of ten years of the use of radioactive colloids in intracavitary therapy. *J Nucl Med* 1960;1:195–198.
125. Jatoi A, Nieva JJ, Qin R, et al. A pilot study of long-acting octreotide for symptomatic malignant ascites. *Oncology* 2012;82:315–320.